 |
Florida Statutes (Last Updated: April 21, 2021) |
 |
TITLE XXIX. PUBLIC HEALTH |
|
CHAPTER 385. CHRONIC DISEASES |
SECTION 385.211. Refractory and intractable epilepsy treatment and research at recognized medical centers.
Latest version.
- 112(1) 3As used in this section, the term “low-THC cannabis” means “low-THC cannabis” as defined in s. 19381.986 20that is dispensed only from a dispensing organization as defined in former s. 33381.986, 34Florida Statutes 2016, or a medical marijuana treatment center as defined in s. 47381.98648.49(2) 50Notwithstanding chapter 893, medical centers recognized pursuant to s. 59381.925, 60or an academic medical research institution legally affiliated with a licensed children’s specialty hospital as defined in s. 78395.002(27) 79that contracts with the Department of Health, may conduct research on cannabidiol and low-THC cannabis. This research may include, but is not limited to, the agricultural development, production, clinical research, and use of liquid medical derivatives of cannabidiol and low-THC cannabis for the treatment for refractory or intractable epilepsy. The authority for recognized medical centers to conduct this research is derived from 21 C.F.R. parts 312 and 316. Current state or privately obtained research funds may be used to support the activities described in this section.
Note
Note.-Section 1, ch. 2017-232, provides that “[i]t is the intent of the Legislature to implement s. 29, Article X of the State Constitution by creating a unified regulatory structure. If s. 29, Article X of the State Constitution is amended or a constitutional amendment related to cannabis or marijuana is adopted, this act shall expire 6 months after the effective date of such amendment.” If such amendment or adoption takes place, subsection (1), as amended by s. 1, ch. 2017-232, will read:
(1) As used in this section, the term “low-THC cannabis” means “low-THC cannabis” as defined in s. 381.986 that is dispensed only from a dispensing organization as defined in s. 381.986.
